In the Media
Dr. Sant Chawla and the oncology team at the Cancer Center of Southern California are world-renowned for their expertise in treating advanced sarcomas and other cancers. They are often sought after for this expertise and their clinical trials are often discussed in the media. Take a look at some of the news articles and videos below to learn more about our oncologists, their clinical trials, and sarcoma expertise. Call us today at 310-552-9999 to learn more.
Listed below are just a few of the most recent publications written by the oncologists at the Sarcoma Oncology Center. Click on each title below to be taken to the full article.
– Phase 1b/2 Aldoxorubicin Clinical Trial Results in Cancer:
- A Phase 1b/2 Study of Aldoxorubicin (INNO-206; EMCH-Doxorubicin) in Patients With Soft Tissue Sarcoma
Study of the safety and efficacy of Aldoxorubicin, a prodrug of Doxrubicin, in patients with recurrent malignant solid tumors, including soft tissue sarcoma. The patients in the clinical trial received intravenous infusions every 3 weeks for a total of 8 cycles. Written by the oncologists of the Sarcoma Oncology Center in collaboration with other leading physicians.
Conclusion: Aldoxorubicin administered at the above-mentioned dose was found to be acceptably safe and showed preliminary efficacy in patients with advanced solid tumors, including soft tissue sarcoma. Further investigation of aldoxorubicin is ongoing.
– Journal of Clinical Oncology:
- Phase II Study of the Safety and Antitumor Activity of Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma.
Written by Dr. Sant Chawla in collaboration with co-authors from Cedars Sinai Medical Center, Stanford University Medical Center, University of Arizona Cancer Center, Washington University, Moffitt Cancer Center and Research Institute, Mayo Clinic, and Dana-Farber Cancer Institute.
Conclusion: PFS, overall survival, and tumor response compared favorably with historical outcomes achieved with other first-line chemotherapies for advanced STS. A phase III study of TH-302 is ongoing (NCT01440088).
– Cancer Discovery:
Summary: Article, co-authored by Dr. Sant Chawla, explains the antitumor activity found in the treatment of soft-tissue sarcoma patients with TH-302.
– A Phase 2b Randomized Clinical Trial published in Jama Oncology:
- First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma
Summary: Written by Dr. Sant P. Chawla in collaboration with Zsuzsanna Papai, MD; Guzel Mukhametshina, MD; Kamalesh Sankhala, MD; Leonid Vasylyev, MD; Alexander Fedenko, MD; Kenneth Khamly, MD; Kristen Ganjoo, MD; Rajnish Nagarkar, MD; Scott Wieland, PhD; Daniel J. Levitt, MD. The objective was to evaluate the efficacy and safety of aldoxorubicin, an albumin-binding prodrug of doxorubicin, vs doxorubicin in patients with advanced soft-tissue sarcoma.
Conclusion: Single-agent aldoxorubicin therapy showed superior efficacy over doxorubicin by prolonging progression-free survival and improving rates of 6-month progression-free survival and tumor response. Aldoxorubicin therapy exhibited manageable adverse effects, without unexpected events, and without evidence of acute cardiotoxicity. Further investigation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.
Other Recent Features
- Aldoxorubicin improves PFS, tumor response in advanced soft-tissue sarcoma – Press Release featured on Healio.com about Dr. Chawla’s Phase 2b Randomized Clinical Trial
- Phase 3 Trial of Aldoxorubicin Raises Hopes published by the Sarcoma Alliance
- Denosumab: Nonsurgery Option for Giant Cell Tumor of Bone Article featured on MedScape
- Dr. Chawla’s featured article in Lancet Oncology journal from July 2013 on ground-breaking work in Giant Cell Tumors
- Lancet Oncology journal article titled Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- Lancet Oncology journal article titled Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
- Targeted Oncology article titled Precision Medicine in Sarcoma Pinpoints Tropomyosin-Related Kinases
Sarcoma Oncology Center’s Clinical Trials News
The oncologists of the Sarcoma Oncology Center are leading the way in clinical drug trials and are constantly involved in cancer research. Over the years, they have made huge strides in discovering new drugs for the advanced treatment of sarcoma. See just a glimpse of their most recent clinical trial news below:
CytRx’s Aldoxorubicin Clinical Trial News
- CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress
- CytRx Announces Aldoxorubicin + Ifosfamide/Mesna Phase 1b Clinical Trial
- CytRx’s Aldoxorubicin
- Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma Highlighted in The Lancet Oncology
- CytRx Highlights Aldoxorubicin Data from its Global Phase 2b Clinical Trial in First-Line Soft Tissue Sarcoma
- Dr. Sant Chawla featured in article titled CytRx (CYTR) Will Present Aldoxorubicin Phase 1b/2 Data at CTOS Annual Meeting published by Street Insider
- PR Newswire press release CytRx Announces the Completion of Enrollment in Pivotal Global Phase 3 Trial Ahead of Schedule highlights Dr. Sant Chawla
Phase II Hypoxia-Activated Prodrug TH-302 with Doxorubicin
- Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Phase III Rapamycin Inhibitor Ridaforolimus vs. Placebo Results
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy.
Contact the Sarcoma Specialists
If you would like to learn more about our doctors and the advanced treatments they provide for sarcoma patients, contact the Sarcoma Oncology Center at 310-552-9999 today. Our doctors and staff are here to help you!
Next, please read about our cancer team.